NCT06190639View on ClinicalTrials.gov

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

PHASE2RecruitingINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG

sintilimab

200 mg once on day 1, every 21 days

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER